2 active not recruiting, 2 completed, 1 terminated, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Primary Peritoneal Serous Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal Serous Adenocarcinoma trials Research Report on Primary Peritoneal Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-03-01 | 2016-07-26 | |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 155 | 2010-04-14 | 2026-07-14 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (4) · Brenner Tumor (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1)
Adnexal Diseases (5) · Fallopian Tube Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gonadal Disorders (4) · Ovarian Diseases (4)
Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Taxes (2) · olaparib (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Mesenchymal Stem Cell Transplantation (1)
National Cancer Institute (NCI) (3) · Mayo Clinic (2) · Vanderbilt-Ingram Cancer Center (1)
United States (5)
Evanthia Galanis, MD (1) · Joyce F Liu (1) · Katherine M Bell-McGuinn (1) · Marta Crispens, MD (1) · Matthew S. Block, M.D., Ph.D. (1) · Panagiotis Konstantinopoulos (1)
PMID 23810467, PMID 25218906, PMID 31708167, PMID 33610319, PMID 37185961
P30CA006516 (2), UM1CA186709 (2), N01CM00071 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), U01CA062490 (1), U10CA027469 (1), U10CA180868 (1)